Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPS NASDAQ:MGTX NASDAQ:PEPG NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$6.28+0.6%$5.46$2.25▼$7.09$602.51M2.211.57 million shs672,509 shsMGTXMeiraGTx$8.72-0.3%$7.93$4.55▼$9.44$701.50M1.34437,303 shs407,473 shsPEPGPepGen$4.57+1.6%$2.98$0.88▼$8.33$149.90M1.961.60 million shs509,536 shsSVRASavara$4.36+5.8%$3.53$1.89▼$4.42$753.57M0.461.32 million shs1.65 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways0.00%-3.68%+10.95%+45.03%-2.48%MGTXMeiraGTx0.00%+12.52%+6.47%+4.18%+49.06%PEPGPepGen0.00%-6.54%-22.28%+215.17%-47.47%SVRASavara0.00%+20.78%+25.65%+68.99%+27.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPSCOMPASS Pathways$6.28+0.6%$5.46$2.25▼$7.09$602.51M2.211.57 million shs672,509 shsMGTXMeiraGTx$8.72-0.3%$7.93$4.55▼$9.44$701.50M1.34437,303 shs407,473 shsPEPGPepGen$4.57+1.6%$2.98$0.88▼$8.33$149.90M1.961.60 million shs509,536 shsSVRASavara$4.36+5.8%$3.53$1.89▼$4.42$753.57M0.461.32 million shs1.65 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPSCOMPASS Pathways0.00%-3.68%+10.95%+45.03%-2.48%MGTXMeiraGTx0.00%+12.52%+6.47%+4.18%+49.06%PEPGPepGen0.00%-6.54%-22.28%+215.17%-47.47%SVRASavara0.00%+20.78%+25.65%+68.99%+27.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPSCOMPASS Pathways 2.67Moderate Buy$16.00154.78% UpsideMGTXMeiraGTx 2.75Moderate Buy$25.67194.34% UpsidePEPGPepGen 2.33Hold$8.4083.81% UpsideSVRASavara 2.78Moderate Buy$7.8379.66% UpsideCurrent Analyst Ratings BreakdownLatest PEPG, CMPS, SVRA, and MGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025MGTXMeiraGTxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/25/2025PEPGPepGenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/25/2025SVRASavaraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025CMPSCOMPASS PathwaysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/23/2025SVRASavaraCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/23/2025SVRASavaraJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$8.00 ➝ $11.0010/21/2025MGTXMeiraGTxRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$29.0010/20/2025SVRASavaraWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$7.0010/14/2025SVRASavaraLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/13/2025CMPSCOMPASS PathwaysBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $14.0010/8/2025CMPSCOMPASS PathwaysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPSCOMPASS PathwaysN/AN/AN/AN/A$2.26 per shareN/AMGTXMeiraGTx$33.28M21.08N/AN/A$0.87 per share10.02PEPGPepGenN/AN/AN/AN/A$3.64 per shareN/ASVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPSCOMPASS Pathways-$155.12M-$1.84N/AN/AN/AN/A-87.89%-57.77%10/30/2025 (Estimated)MGTXMeiraGTx-$147.79M-$2.04N/A22.95N/A-415.39%-314.44%-63.28%11/12/2025 (Estimated)PEPGPepGen-$89.98M-$2.96N/AN/AN/AN/A-92.51%-70.39%11/6/2025 (Estimated)SVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest PEPG, CMPS, SVRA, and MGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025MGTXMeiraGTx-$0.51N/AN/AN/A$7.71 millionN/A11/11/2025Q3 2025SVRASavara-$0.13N/AN/AN/AN/AN/A11/6/2025Q3 2025PEPGPepGen-$0.71N/AN/AN/AN/AN/A10/30/2025Q3 2025CMPSCOMPASS Pathways-$0.40N/AN/AN/AN/AN/A8/14/2025Q2 2025MGTXMeiraGTx-$0.52-$0.48+$0.04-$0.48$8.00 million$3.69 million8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/A8/7/2025Q2 2025PEPGPepGen-$0.85-$0.70+$0.15-$0.70N/AN/A7/31/2025Q2 2025CMPSCOMPASS Pathways-$0.37-$0.38-$0.01-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPSCOMPASS PathwaysN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPSCOMPASS Pathways0.168.828.82MGTXMeiraGTx26.290.880.88PEPGPepGenN/A4.744.74SVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPSCOMPASS Pathways46.19%MGTXMeiraGTx67.48%PEPGPepGen58.01%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipCMPSCOMPASS Pathways3.93%MGTXMeiraGTx7.50%PEPGPepGen5.20%SVRASavara5.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPSCOMPASS Pathways12095.94 million92.17 millionOptionableMGTXMeiraGTx30080.45 million74.41 millionOptionablePEPGPepGen3032.80 million31.09 millionNot OptionableSVRASavara20172.84 million163.63 millionOptionablePEPG, CMPS, SVRA, and MGTX HeadlinesRecent News About These CompaniesSavara (NASDAQ:SVRA) Hits New 1-Year High on Analyst UpgradeOctober 25 at 2:15 AM | americanbankingnews.comSVRA IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Savara Inc. Investors to ...October 24 at 11:00 PM | caledonianrecord.comCSVRA IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action – SVRAOctober 24 at 7:55 PM | globenewswire.comSavara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitOctober 24 at 12:00 PM | prnewswire.comSavara (NASDAQ:SVRA) Reaches New 1-Year High on Analyst UpgradeOctober 24 at 10:25 AM | marketbeat.comClass Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors - Contact Levi & KorsinskyOctober 24 at 9:00 AM | prnewswire.comShareholders That Lost Money on Savara Inc. (SVRA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn MoreOctober 24 at 7:55 AM | theglobeandmail.comJMP Securities Maintains Savara (SVRA) Market Outperform RecommendationOctober 23 at 11:27 PM | msn.comSAVARA CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Investors of the November 7th Deadline in the Filed Class Action LawsuitOctober 23 at 5:35 PM | globenewswire.comInvestors in Savara Inc. Should Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights – SVRAOctober 23 at 4:22 PM | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraOctober 23 at 1:36 PM | prnewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRAOctober 23 at 10:00 AM | prnewswire.comSavara price target raised to $11 from $8 at Citizens JMPOctober 23 at 8:49 AM | msn.comSavara Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 7, 2025 to Discuss Your Rights - SVRAOctober 23 at 8:45 AM | prnewswire.comJMP Securities Boosts Savara (NASDAQ:SVRA) Price Target to $11.00October 23 at 8:18 AM | marketbeat.comSavara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRAOctober 23 at 5:50 AM | prnewswire.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmOctober 23 at 4:28 AM | prnewswire.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud LawsuitOctober 23 at 2:46 AM | prnewswire.comSavara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm ...October 22, 2025 | caledonianrecord.comCSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmOctober 22, 2025 | globenewswire.comROSEN, A LONGSTANDING LAW FIRM, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– SVRAOctober 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePEPG, CMPS, SVRA, and MGTX Company DescriptionsCOMPASS Pathways NASDAQ:CMPS$6.28 +0.04 (+0.64%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$6.30 +0.02 (+0.40%) As of 10/24/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.MeiraGTx NASDAQ:MGTX$8.72 -0.03 (-0.34%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$8.72 +0.00 (+0.06%) As of 10/24/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.PepGen NASDAQ:PEPG$4.57 +0.07 (+1.56%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$4.53 -0.04 (-0.88%) As of 10/24/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Savara NASDAQ:SVRA$4.36 +0.24 (+5.83%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$4.40 +0.04 (+0.94%) As of 10/24/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
